SEATTLE, Sept. 17 Dendreon Corporation(Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., president andchief executive officer of Dendreon, will present a company update at the UBSGlobal Life Sciences Conference in New York City, on Monday, September 22,2008 at 1:30 p.m. ET.
A live audio webcast of the presentation will be accessible through theInvestor Relations section of the Dendreon website, http://www.dendreon.com.If you are unable to listen to the live webcast, it will be archived on thesite following the presentation. To access the replay, go to the InvestorRelations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to targetcancer and transform lives through the discovery, development andcommercialization of novel therapeutics. The Company applies its expertise inantigen identification, engineering and cell processing to produce activecellular immunotherapy product candidates designed to stimulate an immuneresponse. Dendreon is also developing an orally-available small moleculecalled Trp-p8 that could be applicable to multiple types of cancer as well asbenign prostatic hyperplasia. The Company has its headquarters in Seattle,Washington and is traded on the Nasdaq Global Market under the symbol DNDN.For more information about the Company and its programs, visithttp://www.dendreon.com.
SOURCE Dendreon Corporation